HOME >> BIOLOGY >> NEWS
Gene trigger for pancreas formation identified

Before the pancreas is a pancreas, it is just two tiny bumps--two groups of cells sprouting from a central tube. What makes these cells bud off from the main group? How do they go on to make all the cell types of the mature pancreas? These are the kinds of questions that drive the research efforts of Vanderbilt developmental biologist Chris Wright and colleagues. The answers could pave the way toward limitless supplies of pancreatic cells for transplantation therapy of diabetes.

"It has been established that islet cell transplantation can solve the diabetes problem," said Wright, referring to studies carried out in Edmonton, Canada and elsewhere. "The problem is having a suitable and sufficient source of transplantation material."

Donated pancreases and the technical expertise required to isolate functioning islet cells--the pancreatic cells that produce insulin--will not meet the demand, Wright said. An alternative, he said, is to produce insulin-secreting cells from embryonic or other stem cells.

"If we can identify the factors that determine pancreatic cell fate," he said, "we might be able to coerce embryonic stem cells or other cells to turn into pancreas."

One of these factors is a gene called PTF1p48 (p48 for short). Wright and colleagues reported in Nature Genetics, published online August 19, that p48 is required for the development of the pancreas, both its exocrine cells--those that secrete digestive enzymes--and its endocrine cells--those that secrete insulin and other hormones.

Wright's team used what one reviewer of the paper called "a novel and powerful cell marking method" to track cells in the mouse that express the p48 gene, starting very early in embryonic pancreas formation. The method relied on genetic manipulations to introduce an inherited marker--a blue color that could be followed in cells that turned on the p48 gene, and in all the cells that came from those cells.

A simple way to thin
'"/>

Contact: John Howser
john.howser@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
18-Aug-2002


Page: 1 2 3

Related biology news :

1. Algal contact as a trigger for coral disease
2. Study suggests cell-cycle triggers might be cancer drug targets
3. Good bacteria trigger proteins to protect the gut
4. Inflammations trigger finger
5. Sick Kids researchers look at viral triggers for multiple sclerosis in children
6. Molecular mechanisms that trigger flowering in spring
7. Oxygen triggered the evolution of complex life forms
8. Ultra-low oxygen could have triggered die-offs, spurred bird breathing system
9. Retroviral protein triggers proliferation of immune cells
10. Collapse of seals, sea lions & sea otters in North Pacific triggered by overfishing of great whales
11. New compound class found to trigger changes in cell garbage can

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene trigger for pancreas formation identified

(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development ... for the quarter ended June 30, 2015, corporate ... and management report are available at www.sedar.com ... . "RepliCel expects to launch ...
(Date:8/28/2015)... ... ... the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake ... as the Fonz in a lab coat and Large Marge have been posted on the ... , FireflySci is proud to be the only cuvette manufacturer is the world that ...
(Date:8/27/2015)... Reston, VA (PRWEB) , ... August 27, 2015 , ... ... government contractors solve complex business problems, is pleased to announce their ranking as one ... 34th annual ranking of the fastest-growing private companies across the nation. , “It is ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: